Mineral metabolism in patients on chronic peritoneal dialysis

被引:1
作者
Ceballos O, Maria Luisa [1 ]
Rojo L, Angelica [1 ]
Azocar P, Marta [1 ]
Ibacache M, Maria Jose [1 ]
Delucchi B, Angela [1 ]
Quiroz Z, Lily [2 ]
Irarrazabal M, Carlos [3 ]
Delgado B, Iris [4 ]
Ugarte P, Francisca [3 ]
Cano Sch, Francisco [1 ]
机构
[1] Univ Chile, Fac Med, Hosp Luis Calvo Mackenna, Santiago, Chile
[2] Hosp Roberto del Rio, Santiago, Chile
[3] Univ Los Andes, Fac Med, Santiago, Chile
[4] Univ Desarrollo, Fac Med, Clin Alemana, Concepcion, Chile
来源
REVISTA CHILENA DE PEDIATRIA-CHILE | 2014年 / 85卷 / 01期
关键词
Chronic kidney disease; mineral metabolism; bone disease; FGF23; Klotho;
D O I
10.4067/S0370-41062014000100004
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Introduction: Children with chronic kidney disease (CKD) and receiving peritoneal dialysis (PD) have disorders of mineral metabolism that impact their growth, survival and cardiovascular functions. New molecular markers offer a better understanding of the pathophysiology of this disease. Objective: To characterize some components of mineral metabolism, with emphasis on FGF23/Klotho and cardiovascular functions (CV) of these patients. Patients and Method: Prospective observational cohort study. Exclusion criteria: serum 25 (OH) vitamin D < 20 ng/ml, peritonitis within the last two months and active nephrotic syndrome. Calcemia, phosphemia, parathyroid hormone (PTH), 25 (OH) vitD3, 1.25 (OH) vitD3, FGF23 and Klotho in plasma were measured. FGF23 and Klotho were quantified in healthy children as a control group. Echocardiography was performed calculating the left ventricular mass index (LVMI). Descriptive statistics analysis, Pearson correlation coefficient for association among variables and multivariate analysis were conducted. Results: 33 patients, 16 males, aged between 1.2 and 13.4 years were included. Age of onset for PD: 7.3 +/- 5.0 years, time receiving PD: 13.5 +/- 14.5 months. The plasma concentration of 25 (OH) vitD3 was 34.2 +/- 6.3 pg/ml. Calcemia and phosphemia values were 9.8 +/- 0.71 and 5.4 +/- 1.0 mg/dl respectively. PTH was 333 +/- 287 pg/ml. FGF23 in plasma was 225.7 +/- 354.3 pg/ml and Klotho 131.6 +/- 72 pg/ml, and in the controls (n = 16), it was 11.9 +/- 7.2 pg/ml and 320 +/- 119 pg/ml, respectively. The residual and total dose of dialysis (KtV) was 1.6 +/- 1.3 and 2.9 +/- 1.6, respectively. FGF23 levels significantly correlated with calcium (p < 0.001, r = 0.85), and inversely with residual KtV, showing no relationship with phosphemia. Klotho level correlated negatively with residual KtV and also, it showed a negative association with chronological age and age at onset of PD. LVMI > 38 g/m(2) was confirmed in 20/28 patients. Conclusions: The values of FGF23, and PTH are elevated in children with CKD on PD. Klotho levels in CKD patients are lower than control children. A strong association of calcemia with FGF23 and PTH is reported. Residual renal function is inversely associated with FGF23 and Klotho. A high incidence of left ventricular hypertrophy was found evidencing a cardiovascular compromise in these patients.
引用
收藏
页码:31 / 39
页数:9
相关论文
共 26 条
[11]   Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease [J].
Isakova, Tamara ;
Wahl, Patricia ;
Vargas, Gabriela S. ;
Gutierrez, Orlando M. ;
Scialla, Julia ;
Xie, Huiliang ;
Appleby, Dina ;
Nessel, Lisa ;
Bellovich, Keith ;
Chen, Jing ;
Hamm, Lee ;
Gadegbeku, Crystal ;
Horwitz, Edward ;
Townsend, Raymond R. ;
Anderson, Cheryl A. M. ;
Lash, James P. ;
Hsu, Chi-yuan ;
Leonard, Mary B. ;
Wolf, Myles .
KIDNEY INTERNATIONAL, 2011, 79 (12) :1370-1378
[12]   Mutation of the mouse klotho gene leads to a syndrome resembling ageing [J].
Kuroo, M ;
Matsumura, Y ;
Aizawa, H ;
Kawaguchi, H ;
Suga, T ;
Utsugi, T ;
Ohyama, Y ;
Kurabayashi, M ;
Kaname, T ;
Kume, E ;
Iwasaki, H ;
Iida, A ;
ShirakiIida, T ;
Nishikawa, S ;
Nagai, R ;
Nabeshima, Y .
NATURE, 1997, 390 (6655) :45-51
[13]  
Moe S, DEFINITION EVALUATIO
[14]   Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model [J].
Nakatani, Teruyo ;
Ohnishi, Mutsuko ;
Razzaque, M. Shawkat .
FASEB JOURNAL, 2009, 23 (11) :3702-3711
[15]   FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization [J].
Quarles, LD .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2003, 285 (01) :E1-E9
[16]   The wrickkened pathways of FGF23, MEPE and PHEX [J].
Rowe, PSN .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 2004, 15 (05) :264-281
[17]   Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis [J].
Seeherunvong, Wacharee ;
Abitbol, Carolyn L. ;
Chandar, Jayanthi ;
Rusconi, Paolo ;
Zilleruelo, Gaston E. ;
Freundlich, Michael .
PEDIATRIC NEPHROLOGY, 2012, 27 (11) :2129-2136
[18]   Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia [J].
Shimada, T ;
Mizutani, S ;
Muto, T ;
Yoneya, T ;
Hino, R ;
Takeda, S ;
Takeuchi, Y ;
Fujita, T ;
Fukumoto, S ;
Yamashita, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (11) :6500-6505
[19]   Circulating Fibroblast Growth Factor 23 in Patients with End-Stage Renal Disease Treated by Peritoneal Dialysis Is Intact and Biologically Active [J].
Shimada, Takashi ;
Urakawa, Itaru ;
Isakova, Tamara ;
Yamazaki, Yuji ;
Epstein, Michael ;
Wesseling-Perry, Katherine ;
Wolf, Myles ;
Salusky, Isidro B. ;
Jueppner, Harald .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (02) :578-585
[20]   Role of phosphorus in the pathogenesis of secondary hyperparathyroidism [J].
Slatopolsky, E ;
Brown, A ;
Dusso, A .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 37 (01) :S54-S57